In mid-November, Pfizer Inc. unpleasantly surprised UCB Celltech 's investors by putting the CDP 870 Phase III rheumatoid arthritis (RA) program on hold. That it wanted to renegotiate the terms of the licensing agreement came completely out of the blue and led to a 20% dive in Celltech's share price. Few were surprised however, when just two weeks later, having failed to convince Celltech to accept new, altogether less favorable terms, Pfizer announced it would hand back all rights to the compound.
When a Big Pharma hands back a licensed product to its biotech partner, for other than anti-trust reasons, it's generally...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?